Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 118

Sort by

Sort Order Select

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Blood (2019) 134 (Supplement_1): 130.

https://doi.org/10.1182/blood-2019-126787

Published: 2019

Journal Articles

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

Blood (2019) 134 (Supplement_1): 610.

https://doi.org/10.1182/blood-2019-125968

Published: 2019

Journal Articles

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

Blood (2019) 134 (Supplement_1): 393.

https://doi.org/10.1182/blood-2019-131270

Published: 2019

Journal Articles

Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML)

Mark Leick, MD, Irene Scarfò, PhD, Bryan D. Choi, MD PhD, Rebecca Larson, BS, Amanda A Bouffard, Ana Castano, MD, Maria L. Cabral, BS, Andrea Schmidts, MD, Matthew J. Frigault, MD, Marcela V. Maus, MD PhD

Blood (2019) 134 (Supplement_1): 4443.

https://doi.org/10.1182/blood-2019-127154

Published: 2019

Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Nirav N. Shah, MD, Amrita Y. Krishnan, MD, Nina D. Shah, MD, John M Burke, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Leslie L. Popplewell, MD FRCPA, Charalambos B. Andreadis, MD, Saurabh Chhabra, MD, Jeff P. Sharman, MD, Jonathan L. Kaufman, MD, Jonathon B. Cohen, MDMS, Ruben Niesvizky, MD, Thomas G. Martin, III, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS, FACP

Blood (2019) 134 (Supplement_1): 5329.

https://doi.org/10.1182/blood-2019-122754

Published: 2019

Journal Articles

Novel Immunotherapeutic Approaches for Hodgkin Lymphoma

Barbara Savoldo, MD PhD, Natalie S Grover, MD, Carlos A. Ramos, MD, Gianpietro Dotti, MD

Blood (2019) 134 (Supplement_1): SCI-9.

https://doi.org/10.1182/blood-2019-121075

Published: 2019

Journal Articles

A Novel Targeted Approach to Achieve Immune System Reset: CD45-Targeted Antibody Drug Conjugates Enable Autologous HSCT, Ameliorate Disease in Autoimmune Models, Potently Kill Human Immune Cells from Normal Donors and MS Patients, and Achieve Immune Depletion in Non-Human Primates (NHP)

Geoff O Gillard, Jennifer L Proctor, BS, Melissa L. Brooks, BS, Tahirih L Lamothe, BS, Sharon L. Hyzy, MS, Oliver Mikse, Sean McDonough, Rahul Palchaudhuri, PhD, Anjali Bhat, MS, Ganapathy N. Sarma, PhD, Prashant Bhattarai, Pranoti Sawant, MS, Bradley R Pearse, PhD, Charlotte F. Mcdonough, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD

Blood (2019) 134 (Supplement_1): 3208.

https://doi.org/10.1182/blood-2019-130752

Published: 2019

Journal Articles

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Alex F. Herrera, MD, Jasmine Zain, MD, Kerry J Savage, BSc, MD MSc, Tatyana A. Feldman, MD, Jonathan E Brammer, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Lacolle Peters, Yaira Kurtzman, Stephen J Forman, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Swaminathan P. Iyer, MD

Blood (2019) 134 (Supplement_1): 4023.

https://doi.org/10.1182/blood-2019-123166

Published: 2019

Journal Articles

TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion

Harbani Malik, PhD, Ben Buelow, MD PhD, Udaya Rangaswamy, PhD, Aarti Balasubramani, Andrew Boudreau, Kevin Dang, Laura Davison, PhD, Shelley Force Aldred, Katherine Marie Harris, MD, Suhasini Iyer, PhD, Brett Jorgensen, PhD, Duy Pham, MBA, Kirthana Prabhakar, Ute Schellenberger, PhD, Harshad Ugamraj, Nathan Trinklein, PhD, Wim Van Schooten, PhD

Blood (2019) 134 (Supplement_1): 4070.

https://doi.org/10.1182/blood-2019-123226

Published: 2019

Journal Articles

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Adam Zayac, MD, Pamela C Egan, MD, Thomas A Ollila, MD, Adam J Olszewski, MD, Peter Barth, MD, Matthew I. Quesenberry, MD, James Butera, MD, Loren D. Fast, PhD, Rabin Niroula, MBBS, Peter J. Quesenberry, MD, John L Reagan, MD

Blood (2019) 134 (Supplement_1): 4460.

https://doi.org/10.1182/blood-2019-123789

Published: 2019

Journal Articles

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

Lijie Xing, MD, Liang Lin, PhD, Tengteng Yu, MD PhD, Yuyin Li, PhD, Kenneth Wen, BS, Shih-Feng Cho, MD PhD, Phillip A Hsieh, Krista Kinneer, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 1817.

https://doi.org/10.1182/blood-2019-127163

Published: 2019

Journal Articles

Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia

Scott M. Portwood, MBA, MS, Marianna C Cantella, BE, Tara L. Cronin, BA, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 1371.

https://doi.org/10.1182/blood-2019-130427

Published: 2019

Journal Articles

Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models

Patrick R. Hagner, PhD, Michelle Waldman, MS, Falon D. Gray, DVM, DACVP, Renee Yura, PhD, Sarah Hersey, MS, MBA, Henry Chan, PhD, Mingjun Zhang, PhD, Isaac Boss, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 1580.

https://doi.org/10.1182/blood-2019-126115

Published: 2019

Journal Articles

CD79b Expression in Richter's Transformation

John N. Allan, MD, Erica B Bhavsar, BS, Tiziana Vaisitti, PhD, Vincent Sarno, Yifang Liu, Francesca Arruga, PhD, Maureen Joyce, Mathias Schulz, MD MBA, Silvia Deaglio, MD PhD, Richard R. Furman, MD, Amy Chadburn, MD

Blood (2019) 134 (Supplement_1): 4279.

https://doi.org/10.1182/blood-2019-128305

Published: 2019

Journal Articles

Targeting CD45 with an Amanitin Antibody-Drug Conjugate Effectively Depletes Human HSCs and Immune Cells for Transplant Conditioning

Blood (2018) 132 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2018-99-117167

Published: 2018

Journal Articles

CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies

Blood (2018) 132 (Supplement 1): 776.

https://doi.org/10.1182/blood-2018-99-117553

Published: 2018

Journal Articles

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Sham Mailankody, MBBS, Myo Htut, MD, Kelvin P. Lee, MD, William Bensinger, MD, Todd Devries, PhD, Julia Piasecki, BA, Safiyyah Ziyad, PhD, Michelle Blake, PhD, John Byon, MDPhD, Andrzej Jakubowiak, MD PhD

Blood (2018) 132 (Supplement 1): 957.

https://doi.org/10.1182/blood-2018-99-113548

Published: 2018

Journal Articles

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Mehdi Hamadani, MD, Graham P. Collins, MB BS DPhil, Felipe Samaniego, MD, Alexander I Spira, MD, Andrew Davies, John Radford, MD FRCP, Paolo Caimi, MD, Tobias Menne, MD PhD, Joseph Boni, PhD, Hans Cruz, Jay Feingold, MD PhD, Shui He, PhD, Jens Wuerthner, Steven M. Horwitz, MD

Blood (2018) 132 (Supplement 1): 928.

https://doi.org/10.1182/blood-2018-99-118198

Published: 2018

Journal Articles

CD37 Expression in Acute Myeloid Leukemia Provides New Target for Directed Therapy

Karilyn Larkin, MD, Erin Guth, MS, Bonnie K. Harrington, DVM, Nicole Grieselhuber, MD PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 4056.

https://doi.org/10.1182/blood-2018-99-117262

Published: 2018

NARROW

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML)

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Novel Immunotherapeutic Approaches for Hodgkin Lymphoma

A Novel Targeted Approach to Achieve Immune System Reset: CD45-Targeted Antibody Drug Conjugates Enable Autologous HSCT, Ameliorate Disease in Autoimmune Models, Potently Kill Human Immune Cells from Normal Donors and MS Patients, and Achieve Immune Depletion in Non-Human Primates (NHP)

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia

Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models

CD79b Expression in Richter's Transformation

Targeting CD45 with an Amanitin Antibody-Drug Conjugate Effectively Depletes Human HSCs and Immune Cells for Transplant Conditioning

CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

CD37 Expression in Acute Myeloid Leukemia Provides New Target for Directed Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only